The gene therapy developer secured backing from Lundbeck and Alexandria Real Estate Equities in a series B round that will support the advancement of its clinical pipeline.

US-based gene therapy developer Lexeo Therapeutics has raised $100m in a series B round featuring pharmaceutical company Lundbeck and life sciences real estate investment trust Alexandria Real Estate Equities

Asset managers D1 Capital Partners and Eventide Asset management co-led the round and were joined by Verition Fund Management, Laurion Capital Management, Longitude Capital, Gray’s Creek Capital, Omega Funds, Janus Henderson Investors, PBM Capital, Woodline Partners and Invus Capital.

Lundbeck made its commitment through its corporate venturing unit Lundbeckfonden Ventures while…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn